To the Editor:
In essentially every Alzheimer's disease clinical trial, a person with knowledge of the patient, usually the primary caregiver, serves as a proxy source of information. Validated informant-based instruments measure cognition, function, behaviors, and quality of life.
In "Errors in self-reports of health services use: impact on Alzheimer disease clinical trial designs," Chris Callahan and coauthors described the accuracy of informants' reports on yet another type of information: resource utilization by patients with Alzheimer's disease. Their analyses of a subset of data from a randomized controlled trial of a coordinated care model, which successfully enrolled a real world sample of 173 patients with Alzheimer's disease, found poor agreement between informant reports and objective health care utilization data. Informants most often underreported resource utilization. Modeling the impact of this poor agreement on statistical power shows that trials that use informant-based resource utilization outcomes, compared with trials using objective data, will need to increase their sample sizes by as many as 150 patients per arm.
The authors acknowledged limitations of their study, including the lack of private payer and self-pay utilization data and that the cost of assembling the objective dataset, even without private payer information, may outweigh the cost associated with simply increasing trial sample sizes. One additional limitation should be noted as well, a limitation that could have important implications to planning future clinical trials.
The subanalysis included 100 subjects, selected because of their enrollment at an urban safety net health system. This selection may have resulted in an important sample bias. In the original trial, 42% of the cohort was composed of spousal dyads, but in the current study the sample included only 17 spousal dyads (17%).
Why does this matter? Several studies suggest that relationship to the patient may be associated with bias in informant-based outcomes reporting. Nonspousal informants are, for example, more likely to provide discrepant measures of memory, orientation, and problem solving and are also more likely to be replaced during the study or dropout before its completion. Each of these can increase variance. The inclusion of a preponderance of nonspousal informants from the original trial may have therefore inflated the discrepancy observed between informant report and objective data, relative to the entire original trial sample or, even more so, compared with most Alzheimer's disease clinical trialswhere spousal caregivers predominate.
Enrollment of underrepresented populations, such as those lacking a spouse, in clinical trials must be increased. Such increases, however, may also necessitate developing methods to reduce informant bias, improve accuracy, and retain participants and study partners. Further studies of predictors of accuracy for informantbased outcomes are also needed. Collectively, these advances will enhance our ability to detect positive outcomes for effective interventions and to do so in an accelerated timeline.
Joshua D. Grill, PhD* Jason Karlawish, MDw In Reply:
We would thank the authors for highlighting the measurement problems associated with caregiver reports of care-recipient function and health care utilization. Drs Grill and Karlawish correctly highlighted a potential limitation in the generalizability of our findings of errors of self-reports of health services use. Our team has focused particularly on enrolling underrepresented minority and urban poor older adults in clinical trials. These subjects are characterized not only by lower educational attainment, fractured social networks, and low income, but also multimorbidity. Many are older women who developed dementia long after their spouse died and therefore rely on other caregivers. Any of these issues could result in differential rates of selfreporting errors. In our review of the literature, however, we did not find studies that reported greater accuracy among spouse-caregivers compared with other caregivers or other studies that compared these self-reports to objective claims data. We would like to highlight 2 additional issues relevant to the generalizability of our sample population. First, the subsample we report differs from the original clinical trial because we could not access similar objective health services utilization data in the Veteran sample. The Veteran sample was more likely to have a spouse-caregiver. Second, there is an important and growing group of vulnerable elders who were not enrolled in our trial (or any other trial). Namely, older adults living with dementia who are unable to identify a caregiver or whose caregiver is unwilling or unable to provide informed consent to engage in a clinical trial.
Compared with the other important outcomes noted by Grill and Karlawish, health care utilization has the advantage of having an objective standard. We can know, for example, whether a hospitalization or nursing home stay actually occurred and we can know whether one did not occur and we can know this within very specific timeframes. The studies noted by Grill and Karlawish, however, focus on caregiver reports of care-recipient function. In the studies noted by Grill and Karlawish, we can know that information sources differ in their reports of care-recipient function, but we cannot know whose report is the most accurate, valid, or important. We especially must recognize that every source has the potential for bias. For
